Evidence & concentration worksheet · Growth Hormone & Performance
CJC-1295 NO DAC 5 mg
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
Evidence review
No established human dosing protocol
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
How it works
CJC-1295 without DAC is the 29-amino-acid GHRH analogue that FDA calls CJC-1295 free base; its acetate salt is a separate bulk drug substance. It lacks the albumin-binding Drug Affinity Complex used in the long-acting DAC active moiety.[1]
Online names such as no DAC and modified GRF (1-29) are used inconsistently. FDA found mismatches among names, structures, identifiers, certificates of analysis, and cited studies, so a product name alone does not establish identity.[1]
Benefits & side effects
FDA found no human study of CJC-1295 free base or acetate without DAC and no human effectiveness study of any form in growth hormone deficiency. A terminated HIV-visceral-obesity trial did not identify which form it intended to study and produced no usable clinical result.[1][3]
Claims about muscle, fat loss, sleep, recovery, anti-aging, dosing frequency, or duration are therefore unsupported extrapolations from a different active moiety or from general GHRH biology.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- U.S. FDA — FDA evaluation of CJC-1295-related bulk drug substances (2024)
- Journal of Clinical Endocrinology & Metabolism — Prolonged GH and IGF-1 secretion after the DAC active moiety in healthy adults (2006)
- ClinicalTrials.gov — Terminated study of CJC-1295 in HIV-associated visceral obesity (2006)
- U.S. FDA — Bulk substances that may present significant compounding safety risks (2026)
- World Anti-Doping Agency — 2026 Prohibited List (2026)